Earth Science Tech Inc. (OTC: ETST) reported third fiscal quarter 2026 revenue of $8.4 million, representing a 14.1% year-over-year increase. The company's gross profit rose to $6.4 million, resulting in gross margin expansion to 76.3% compared to 69.2% in the previous fiscal year. This margin improvement highlights enhanced operating leverage across ETST's portfolio of high-potential operating businesses.
The company simultaneously announced significant governance reforms and cost initiatives designed to optimize its financial performance. These strategic measures are projected to generate approximately $1.4 million in annualized savings. According to the company, this transformation positions ETST for disciplined growth focused on expanding margins, optimizing cash generation, and adopting a more shareholder-focused public company model.
The financial implications of these announcements are substantial. The combination of revenue growth, margin expansion, and cost savings initiatives signals a projected net income growth trajectory exceeding 40%. This represents a pivotal shift for the strategic holding company as it transitions into what it describes as a new era of profitability and governance excellence.
For investors and industry observers, these developments indicate ETST's commitment to operational efficiency and shareholder value creation. The improved gross margin of 76.3% demonstrates the company's ability to enhance profitability even as revenue grows, suggesting effective management of its acquired businesses. The governance reforms further signal a maturation of the company's corporate structure and strategic direction.
The broader impact extends to the biotechnology and life sciences sectors where ETST operates. As companies in these competitive fields seek sustainable growth models, ETST's focus on margin expansion and cost optimization provides a case study in balancing acquisition-driven growth with operational discipline. The company's latest news and updates remain available in its newsroom at https://ibn.fm/ETST.
This press release was distributed through BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences developments. BioMedWire is part of the Dynamic Brand Portfolio at IBN, providing wire solutions, editorial syndication, press release enhancement, and social media distribution. More information about BioMedWire is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.
